Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice
JG Hyun, G Lee, JB Brown, GR Grimm… - Inflammatory bowel …, 2005 - academic.oup.com
Inflammatory bowel diseases, 2005•academic.oup.com
Background Colitis in interleukin (IL)-10−/− mice is a CD4+ T helper 1 (TH1)-mediated
disease characterized by intermittent, transmural inflammation reminiscent of human
Crohn's disease. In this study, we investigated the hypothesis that production of the CXC
chemokine CXCL10 (interferon [IFN] γ-inducible protein 10) enhances induction of
inflammatory responses in draining lymph nodes (LNs) and promotes colonic TH1 cell
recruitment. Methods Colitis was induced in B6 IL-10−/− mice. Mice were given anti-CXCL10 …
disease characterized by intermittent, transmural inflammation reminiscent of human
Crohn's disease. In this study, we investigated the hypothesis that production of the CXC
chemokine CXCL10 (interferon [IFN] γ-inducible protein 10) enhances induction of
inflammatory responses in draining lymph nodes (LNs) and promotes colonic TH1 cell
recruitment. Methods Colitis was induced in B6 IL-10−/− mice. Mice were given anti-CXCL10 …
Background
Colitis in interleukin (IL)-10−/− mice is a CD4+ T helper 1 (TH1)-mediated disease characterized by intermittent, transmural inflammation reminiscent of human Crohn's disease. In this study, we investigated the hypothesis that production of the CXC chemokine CXCL10 (interferon [IFN]γ-inducible protein 10) enhances induction of inflammatory responses in draining lymph nodes (LNs) and promotes colonic TH1 cell recruitment.
Methods
Colitis was induced in B6 IL-10−/− mice. Mice were given anti-CXCL10 mAb in 2-week intervals before and after peak colitis. Colitis severity was graded and cytokine/chemokine levels were analyzed by real-time polymerase chain reaction. Cell yields were quantitated and effector cell recruitment was assessed by recovery of transferred D011.10 TH1 cells shortly (72 h) after transfer.
Results
Treatment with anti-CXCL10 during colitis development decreased clinical and histologic disease severity as well as cytokine/chemokine mRNA and accumulation of mononuclear cells in LNs and colon. Treatment of mice with severe colitis reduced colitis scores and cell yields to lesser degrees. Anti-CXCL10 specifically decreased recruitment of transferred TH1 cells into mesenteric LNs (MLNs) and colon of IL-10−/− mice by 75% (P < 0.05).
Conclusion
These results suggest that CXCL10 plays a dual role in colitis development by enhancing TH1 cell generation in inductive sites and promoting effector cell recruitment to inflamed tissue. Blockade of CXCL10 may be a useful adjunct to remission-inducing therapies in inflammatory bowel disease (IBD) by impairing disease recurrence through selective inhibition of effector cell generation and trafficking in vivo.
Oxford University Press